| Income Statement | 2026-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 3,227 | 9,027 | ||
| Cost of revenue | NaN | 4,725 | ||
| Gross profit | NaN | 4,302 | ||
| Research and development | 20,036 | 2,694 | ||
| General and administrative | 5,897 | 6,944 | ||
| Total operating expenses | 25,933 | 9,638 | ||
| Loss from operations | -22,706 | -5,336 | ||
| Interest income | 4,384 | NaN | ||
| Other expense, net | -3 | -4 | ||
| Gain (loss) from litigation settlement | NaN | -366 | ||
| Interest income (expense), operating | NaN | -713 | ||
| Total other income, net | 4,381 | -1,083 | ||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | NaN | -6,419 | ||
| Income tax expense (benefit) | NaN | 1 | ||
| Net loss | -18,325 | -6,420 | ||
| Net unrealized loss on marketable securities held | -283 | NaN | ||
| Comprehensive loss | 18,608 | NaN | ||
| Basic EPS | -0.38 | -0.04 | ||
| Diluted EPS | -0.38 | -0.04 | ||
| Basic Average Shares | 48,630,038 | 154,426,333 | ||
| Diluted Average Shares | 48,630,038 | 154,426,333 | ||
Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. (AKTS)